MARKET

PALI

PALI

Palisade Bio Inc
NASDAQ
0.1145
+0.0168
+17.20%
Pre Market: 0.1229 +0.0084 +7.34% 07:00 10/05 EDT
OPEN
0.1000
PREV CLOSE
0.0977
HIGH
0.1288
LOW
0.0990
VOLUME
44.38K
TURNOVER
--
52 WEEK HIGH
3.020
52 WEEK LOW
0.0900
MARKET CAP
8.16M
P/E (TTM)
0.3073
1D
5D
1M
3M
1Y
5Y
Why Vicinity Motor Is Trading Higher By Over 65%; Here Are 26 Stocks Moving Premarket
Gainers Vicinity Motor Corp. (NASDAQ: VEV) rose 65.4% to $1.72 in pre-market trading. Vicinity Motor started deliveries of the first Class 3 electric truck to roll off the assembly line in Canada.
Benzinga · 35m ago
Palisade Bio Announces Oral Presentation Of Phase 2 Data At The American College Of Surgeons Clinical Congress 2022 Oct 17
Carlsbad, CA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.(NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today
Benzinga · 5d ago
Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it had made equity grants to ...
GlobeNewswire · 09/23 20:30
Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference
Live video webcast fireside chat on Thursday, September 29th at 11:30 AM ETCARLSBAD, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastroin...
GlobeNewswire · 09/21 13:23
Palisade Bio Streamlines Operations To Focus Lead Clinical Program
Benzinga · 09/15 15:57
Palisade Bio streamlines operations, including cutting 20% of employees
Palisade Bio (NASDAQ:PALI) is undergoing a <a href="https://se...
Seekingalpha · 09/15 13:02
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company&#39;s Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
Benzinga · 09/14 07:58
Palisade Bio Granted U.S. Patent Titled 'Administration of serine protease inhibitors to the stomach'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=11439611.PN.&amp;OS=PN/1143961
Benzinga · 09/13 20:15
More
About PALI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing oral therapies that target diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal (GI) tract. Its lead therapeutic candidate, LB1148, is an oral liquid formulation of the digestive enzyme inhibitor, tranexamic acid, intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from, among other things, reduced blood flow to the intestine, infections, or due to surgery. Its LB1148 has been advanced to Phase III clinical trials for the return of bowel function indication, which is a protease inhibitor that helps to restore bowel function and reduce abdominal adhesions following surgery.

Webull offers kinds of Palisade Bio Inc stock information, including NASDAQ:PALI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PALI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PALI stock methods without spending real money on the virtual paper trading platform.